Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.

Aprea Therapeutics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

EARLY EVIDENCE OF DISEASE CONTROL WAS OBSERVED IN THE ONGOING PHASE 1 ACESOT-1051 TRIAL, WITH THREE PATIENTS ACHIEVING STABLE DISEASE IN THE 70 MG AND 100 MG COHORTS TREATED WITH THEWEE1 INHIBITOR, APR-1051

APREA THERAPEUTICS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES A CLINICAL UPDATE

PRECLINICAL DATA DEMONSTRATE POTENT SINGLE-AGENT AND COMBINATION EFFECTS IN HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) MODELS, INCLUDING SYNERGY WITH ANTIPD-1 THERAPY

APREA REPORTS ANTI-PROLIFERATIVE RESULTS AND PROMISING EARLY-STAGE CLINICAL DATA FOR NEXT-GENERATION WEE1 INHIBITOR, APR-1051, IN HPV+ HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) IN COLLABORATION WITH MD ANDERSON CANCER CENTER

ATRN-119, OUR ATR INHIBITOR, EXHIBITS EARLY EVIDENCE OF SINGLE AGENT, ANTI-TUMOR ACTIVITY AND IS PROGRESSING TOWARD THE RECOMMENDED PHASE 2 DOSE (RP2D) IN THE ONGOING ABOYA-119 CLINICAL TRIAL

APREA THERAPEUTICS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND PROVIDES A CLINICAL UPDATE

ACESOT-1051 TRIAL EXPANDED TO INCLUDE HPV+ HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) PATIENTS, TARGETING POPULATIONS MOST LIKELY TO BENEFIT FOR WEEI INHIBITION ACESOT-1051 TRIAL EXPANDED TO INCLUDE HPV+ HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) PATIENTS, TARGETING POPULATIONS MOST LIKELY TO BENEFIT FOR WEEI INHIBITION

APREA THERAPEUTICS ANNOUNCES DOSING OF PATIENT WITH HPV+ HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) IN ONGOING ACESOT-1051 TRIAL

ACESOT-1051 TRIAL EVALUATING WEE1 KINASE INHIBITOR APR-1051 NOW ENROLLING PATIENTS IN COHORT 5; OPEN LABEL SAFETY AND EFFICACY DATA EXPECTED H2 2025 TWICE DAILY (BID) DOSING REGIMEN IN ONGOING ABOYA-119 TRIAL EXPECTED TO MAXIMIZE CLINICAL BENEFIT OF ATR INHIBITOR ATRN-119; PLAN TO COMPLETE DOSE ESCALATION H2 2025 $22.8 MILLION IN CASH AND CASH EQUIVALENTS AS OF DECEMBER 31, 2024 DOYLESTOWN, PA., MARCH 25, 2025 (GLOBE NEWSWIRE) -- APREA THERAPEUTICS, INC.(NASDAQ: APRE) (APREA, OR THE COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING INNOVATIVE TREATMENTS THAT EXPLOIT SPECIFIC CANCER CELL VULNERABILITIESWHILE MINIMIZING DAMAGE TO HEALTHY CELLS, TODAY REPORTED FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FULL YEAR ENDED DECEMBER 31, 2024, AND PROVIDED A BUSINESS UPDATE.

APREA THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS AND PROVIDES A BUSINESS UPDATE

DOYLESTOWN, PA., MARCH 11, 2025 (GLOBE NEWSWIRE) -- APREA THERAPEUTICS, INC.(NASDAQ: APRE) (APREA, OR THE COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING INNOVATIVE TREATMENTS THAT EXPLOIT SPECIFIC CANCER CELL VULNERABILITIESWHILE MINIMIZING DAMAGE TO HEALTHY CELLS, ANNOUNCED TODAY THAT IT HAS ENTERED INTO A MATERIAL TRANSFER AGREEMENT (MTA) WITH MD ANDERSON CANCER CENTER. UNDER THE AGREEMENT, APREA WILL SUPPLY ITS PROPRIETARY WEE1 KINASE INHIBITOR, APR-1051, TO SUPPORT PRECLINICAL RESEARCH AIMED AT EXPLORING ITS POTENTIAL IN TREATING HPV+ AND HPV- HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) EXPRESSING GENOMIC MARKERS OF REPLICATION STRESS.

APREA THERAPEUTICS ANNOUNCES AGREEMENT WITH MD ANDERSON CANCER CENTER TO EXPLORE APR-1051 AS A POTENTIAL TREATMENT FOR HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)

DOYLESTOWN, PA., FEB. 05, 2025 (GLOBE NEWSWIRE) -- APREA THERAPEUTICS, INC.(NASDAQ: APRE) (APREA, OR THE COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING INNOVATIVE TREATMENTS THAT EXPLOIT SPECIFIC CANCER CELL VULNERABILITIESWHILE MINIMIZING DAMAGE TO HEALTHY CELLS, TODAY PROVIDED AN UPDATE ON ITS EXISTING PATENT PORTFOLIO.

APREA THERAPEUTICS ANNOUNCES STRATEGIC IP PORTFOLIO EVOLUTION IN DNA DAMAGE RESPONSE (DDR) CANCER THERAPEUTICS

TWICE DAILY (BID) DOSING REGIMEN EXPECTED TO MAXIMIZE CLINICAL BENEFIT FOR PATIENTS BY OPTIMIZING THE ACTIVITY OF APREA'S EXPERIMENTAL DRUG, ATRN-119, OVER A 24-HOUR DAILY CYCLE

APREA THERAPEUTICS ANNOUNCES TWICE DAILY (BID) DOSING OF PATIENTS IN ABOYA-119 CLINICAL TRIAL OF ATRN-119 TO POTENTIALLY OPTIMIZE CLINICAL OUTCOMES AND STRENGTHEN CLINICAL PATH FORWARD

PHASE 1 ACESOT-1051CLINICAL TRIAL IS EVALUATING APR-1051 AS MONOTHERAPY TREATMENT IN PATIENTS WITH SIGNIFICANT UNMET MEDICAL NEED; ACTIVE ENROLLMENT IS ONGOING AT THREE SITES IN THE U.S.

APREA THERAPEUTICS PRESENTS PRELIMINARY FINDINGS ON ORAL WEE1 INHIBITOR APR-1051 AT EORTC-NCI-AACR INTERNATIONAL CONFERENCE ON MOLECULAR TARGETS AND THERAPEUTICS

DOYLESTOWN, PA., OCT. 14, 2024 (GLOBE NEWSWIRE) -- APREA THERAPEUTICS, INC.(NASDAQ: APRE) (APREA, OR THE COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON PRECISION ONCOLOGY THROUGH SYNTHETIC LETHALITY, TODAY ANNOUNCED THAT DR. OREN GILAD, PRESIDENT AND CEO, WILL PARTICIPATE IN TWO PRESENTATIONS AT THE MAXIM HEALTHCARE VIRTUAL SUMMIT, TO TAKE PLACE OCTOBER 15 TO 17, 2024.

APREA THERAPEUTICS TO PRESENT AT MAXIM 2024 HEALTHCARE VIRTUAL SUMMIT

DOYLESTOWN, PA., OCT. 10, 2024 (GLOBE NEWSWIRE) -- APREA THERAPEUTICS, INC.(NASDAQ: APRE) (APREA, OR THE COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON PRECISION ONCOLOGY THROUGH SYNTHETIC LETHALITY, TODAY ANNOUNCED THAT FOUR ABSTRACTS HAVE BEEN ACCEPTED FOR POSTER PRESENTATION AT THE EORTC-NCI-AACR SYMPOSIUM ON MOLECULAR TARGETS AND CANCER THERAPEUTICS, TO TAKE PLACE IN BARCELONA, SPAIN, OCTOBER 23 - 25, 2024. DETAILS ON THE POSTERS ARE BELOW.

Aprea Therapeutics, Inc.

APRE

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Aprea Therapeutics, Inc.

APRE.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

APRE